Takeda Pharmaceutical Company Ltd is to pay $60 million upfront to buy the privately-owned US developer of vaccine technology, LigoCyte Pharmaceuticals Inc. The acquisition will give Takeda a candidate product to prevent norovirus gastroenteritis. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
